Evidence mapPaperPMID 35596567Full record

ArticleJournal of diabetes science and technology2023

Predicting Response to Bolus Insulin Therapy in Patients With Type 2 Diabetes.

Elizabeth L Eby, Neal R Kelly, Jeffrey K Hertzberg, Moira C Blodgett, Callie Stubbins, Raja H Patel, Eric S Meadows, Brian D Benneyworth, Douglas E Faries

Open access · bronzeAbstract read
In one paragraph

Article in Journal of diabetes science and technology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Elizabeth L EbyEli Lilly and Company, Indianapolis, IN, USA.ORCID 0000-0003-3896-6583
Neal R KellyOptum Labs, Minneapolis, MN, USA.
Jeffrey K HertzbergOptum Labs, Minneapolis, MN, USA.
Moira C BlodgettOptum Labs, Minneapolis, MN, USA.
Callie StubbinsOptum Labs, Minneapolis, MN, USA.ORCID 0000-0003-4624-1590
Raja H PatelOptum Labs, Minneapolis, MN, USA.
Eric S MeadowsEli Lilly and Company, Indianapolis, IN, USA.
Brian D BenneyworthEli Lilly and Company, Indianapolis, IN, USA.
Douglas E FariesEli Lilly and Company, Indianapolis, IN, USA.
Optum (United States) · USEli Lilly (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of this study was to develop a predictive model to classify people with type 2 diabetes (T2D) into expected levels of success upon bolus insulin initiation.

methodsMachine learning methods were applied to a large nationally representative insurance claims database from the United States (dNHI database; data from 2007 to 2017). We trained boosted decision tree ensembles (XGBoost) to assign people into Class 0 (never meeting HbA1c goal), Class 1 (meeting but not maintaining HbA1c goal), or Class 2 (meeting and maintaining HbA1c goal) based on the demographic and clinical data available prior to initiating bolus insulin. The primary objective of the study was to develop a model capable of determining at an individual level, whether people with T2D are likely to achieve and maintain HbA1c goals. HbA1c goal was defined at <8.0% or reduction of baseline HbA1c by >1.0%.

resultsOf 15 331 people with T2D (mean age, 53.0 years; SD, 8.7), 7800 (50.9%) people met HbA1c goal but failed to maintain that goal (Class 1), 4510 (29.4%) never attained this goal (Class 0), and 3021 (19.7%) people met and maintained this goal (Class 2). Overall, the model's receiver operating characteristic (ROC) was 0.79 with greater performance on predicting those in Class 2 (ROC = 0.92) than those in Classes 0 and 1 (ROC = 0.71 and 0.62, respectively). The model achieved high area under the precision-recall curves for the individual classes (Class 0, 0.46; Class 1, 0.58; Class 2, 0.71).

conclusionsPredictive modeling using routine health care data reasonably accurately classified patients initiating bolus insulin who would achieve and maintain HbA1c goals, but less so for differentiation between patients who never met and who did not maintain goals. Prior HbA1c was a major contributing parameter for the predictions.

Indexed as

Diabetes Mellitus, Type 2InsulinBlood GlucoseGlycated HemoglobinHumansHypoglycemic AgentsInsulin, Regular, HumanMiddle AgedBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinInsulin, Regular, HumanHbA1cinsulintype 2 diabetes

Identifiers

PMID35596567
PMCPMC10658685
OpenAlexW4281250267

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.